Related Experiment Video
Updated: Aug 4, 2026

Exploring m6A and m5C Epitranscriptomes upon Viral Infection: an Example with HIV
Published on: March 5, 2022
Role of m6A methyltransferase component VIRMA in multiple human cancers (Review)
Wei Zhu1,2, Jing-Zi Wang3, Ji-Fu Wei4,5
1Precision Medicine Center, First Affiliated Hospital of Gannan Medical University, 128 Jinling Road, Ganzhou, 341000, China.
Abstract:
N6-Methyladenosine (m6A) modification is one of the most widely distributed RNA modifications in eukaryotes. It participates in various RNA functions and plays vital roles in tissue development, stem cell formation and differentiation, heat shock response control, and circadian clock controlling, particularly during tumor development. The reversible regulation of m6A modification is affected by the so-called 'reader', 'writer' and 'eraser'. As a required component and the largest methyltransferase, vir-like m6A methyltransferase associated (VIRMA) can promote the progression of cancer and is associated with poor survival in multiple types of cancer. The present review investigated the role of VIRMA in various types of cancer. In an m6A-dependent or -independent manner, VIRMA can play an oncogenic role by regulating cancer cell proliferation, migration and invasion, metastasis, apoptosis resistance and tumor growth in different pathways by targeting stem factors, CCAT1/2, ID2, GATA3, CDK1, c-Jun, etc. VIRMA can also predict better prognosis in kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP) and papillary thyroid carcinoma by TCGA analysis. The obvious oncogenic roles of VIRMA observed in different types of cancer and the mechanisms of VIRMA promoting cancers provided the basis for potential therapeutic targeting for cancer treatments.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Mechanisms of Retrovirus-induced Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
Mechanisms of Retrovirus-induced Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

